{"id":"W2002307343","doi":"10.1517/13543784.2011.549125","title":"AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer","year":2011,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation; Amgen (Canada)","funders":"","keywords":"Angiopoietin 2; Ovarian cancer; Medicine; Angiogenesis; Malignancy; Cancer; Oncology; Antagonist; Internal medicine; Disease; Tumor progression; Overall survival; Cancer research; Receptor; VEGF receptors; Vascular endothelial growth factor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001165118,0.0003639456,0.0005844155,0.0001280853,0.00005439119,0.00001197232,0.0002717579,0.000316407,0.0001111351],"category_scores_gemma":[0.00002708114,0.0002831826,0.0002202739,0.0002154259,0.0002081039,0.00000606119,0.00008031088,0.0001274452,0.000007925712],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007297711,"about_ca_system_score_gemma":0.0008348334,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001886145,"about_ca_topic_score_gemma":0.000008725935,"domain_scores_codex":[0.9983788,0.00007426866,0.0005041531,0.0005440677,0.0002735197,0.0002252508],"domain_scores_gemma":[0.9989678,0.00001931993,0.0004133173,0.0003481868,0.0001466875,0.0001046939],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001420163,0.004621421,0.01065355,0.009651144,0.002053324,0.000002207607,0.001662528,0.0001502799,0.0008986826,0.02102371,0.09687234,0.8509907],"study_design_scores_gemma":[0.0008606376,0.0002220308,0.001346423,0.004008482,0.00001338998,8.850783e-7,0.00001094848,0.000003889654,0.0003945568,0.000007980599,0.9927477,0.0003831352],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005095742,0.9966407,0.00004167122,0.00006111561,0.0003840597,0.0007572261,0.0007250849,0.000008738372,0.0008717791],"genre_scores_gemma":[0.0004595034,0.9925082,0.001430433,0.0003357153,0.0005245929,0.0006561367,0.003745301,0.00007899902,0.0002610827],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8958753,"threshold_uncertainty_score":0.999962,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0426732515451642,"score_gpt":0.3193840067145453,"score_spread":0.276710755169381,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}